Journal
VIROLOGY JOURNAL
Volume 8, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1743-422X-8-525
Keywords
Bifidobacterium; Coxsackievirus B; Enterovirus; Interferon; Myocarditis; Oral administration
Categories
Funding
- Shenzhen scientific Research Program of the People's Republic of China [200801020, 201001023]
- Science and Technology Planning Project of Guangdong Province, China [2010B011000005]
Ask authors/readers for more resources
Multiple reports have claimed that low-dose orally administered interferon (IFN)-alpha is beneficial in the treatment of many infectious diseases and provides a viable alternative to high-dose intramuscular treatment. However, research is needed on how to express IFN stably in the gut. Bifidobacterium may be a suitable carrier for human gene expression and secretion in the intestinal tract for the treatment of gastrointestinal diseases. We reported previously that Bifidobacterium longum can be used as a novel oral delivery of IFN-alpha. IFN-transformed B. longum can exert an immunostimulatory role in mice; however the answer to whether this recombinant B. longum can be used to treat virus infection still remains elusive. Here, we investigated the efficacy of IFN-transformed B. longum administered orally on coxsackie virus B3 (CVB3)-induced myocarditis in BALB/c mice. Our data indicated that oral administration of IFN-transformed B. longum for 2 weeks after virus infection reduced significantly the severity of virus-induced myocarditis, markedly down regulated virus titers in the heart, and induced a T helper 1 cell pattern in the spleen and heart compared with controls. Oral administration of the IFN-transformed B. longum, therefore, may play a potential role in the treatment of CVB3-induced myocarditis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available